Abstract
PD1 is an inhibitory receptor exposed on the surface of T cells and other immune cells. In non-small cell lung cancer and melanoma P, as well as after stem cell transplantation, higher levels of CD4+ T cells (TCD4) expressing PD1 (PD1+) correlated with poor survival outcomes. Nonetheless, in vitro PD1 blockade enhanced antitumor immunity. Finally, subpopulations of TCD4 with higher or lower PD1+ levels were identified and associated with differential functional effects and prognosis in follicular lymphoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
